2436 results about "Biotin" patented technology

The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a personal care, cosmetic, and / or dermopharmaceutical composition comprising oleanolic acid, apigenin, biotinyl-GHK, and at least one additional ingredient, and 4) a method for treating hair loss comprising the administration of oleanolic acid, apigenin, and biotinyl-GHK.

Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells in the isolated Lin− HSCs express the cell surface antigen CD31. The isolated Lin− HSC populations are useful for treatment of ocular vascular diseases. In a preferred embodiment, the Lin− HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin− HSC population containing EPCs. Isolated Lin− HSCs that have been transfected with therapeutically useful genes are also provided, and are useful for delivering genes to the eye for cell-based gene therapy. Methods of preparing isolated stem cell populations of the invention, and methods of treating ocular diseases and injury are also described.

A novel composition for treating nervous system disorders. The composition is formed by preparing a mixture comprising an effective amount of vitamin B-6, folic acid, vitamin C, magnesium, vitamin B-3, copper, probiotics, fructo-oligosaccharide (FOS), betaine, pancreatin, papain, pepsin, vitamin B-1, vitamin B-2, vitamin B-12, biotin, pantothenic acid, chromium polynicotinate and a digestive support ingredient selected from the group consisting of dandelion root, juniper, aloe vera, burdock, ginger root, artichoke, and kelp. Other ingredients may include: beta carotene, vitamin E, selenium, zinc, sea vegetation, alfalfa, trace minerals and molybdenum.

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ biotin ligase and biotin analogs.

The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

The invention relates to a method for producing triglyceride type docosahexenoic acid fat by industrially fermenting schizochytrium. The method comprises the following step: the docosahexenoic acid fat is prepared by fermenting the schizochytrium taken as the strain with the a culture medium with microelements; wherein the culture medium with the microelements comprises a carbon source, a nitrogen source, inorganic salt and microelements, and the microelements comprise at least one of biotin, chlorophyll, beta-carotene, vitaminB1, vitaminB6 and vitaminB12. The prepared docosahexenoic acid fat does not need to be further chemically modified and can be directly used by people needing DHA, including infants, pregnant women, breast feeding women or patients who suffer from diseases due to insufficient DHA and need to supplement DHA. The invention has the advantages of high DHA content, high purity, safe and reliable quality, low production cost, stable production and almost no EPA; and the environmental-friendly, safe and high-content triglyceride type DHA fat can be produced with low cost at a large scale.

The invention relates to an intermedin analogue prepared by bonding a ring core sequence with biotin or cell-penetrating peptides and a preparation method and application of the intermedin analogue. The intermedin analogue is prepared by bonding a functional unit with the biotin or a load unit; the functional unit is a seven-peptide structure formed by connecting the ring core sequence c (Asp-Dab-D-Phe-Arg-Trp-Lys) with a connection unit Arg, the structure is Arg-c (Asp-Dab-D-Phe-Arg-Trp-Lys); the load unit is the 48th-57th peptide segments Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg or the 55th-57th peptide segments Arg-Arg-Arg in the 47th-60th segments of HIV (human immunodeficiency virus)-1TAT protein. The intermedin analogue disclosed by the invention can penetrate through mucosa or skin to be absorbed, and can be applied to treatment of diseases such as male and female sexual dysfunction, obesity, pigmentation deficiency and the like.

The present invention provides a substrate of TGase represented by (fluorescent group)-(linker)-(a portion containing a Gln residue capable of recognition by transglutaminase (TGase))-R, wherein the fluorescent group is fluorescein isothiocyanate (FITC), Texas Red (TE) or dansyl (Dns) or a group derived therefrom; the linker is a group represented by —NH—(CH2)n—CO— (n is an integer of 1 to 6); the portion containing a Gln residue capable of recognition by TGase is a group derived from a peptide selected from among QG and the like; and R is a hydroxyl group, or biotin, nucleic acid, azide, alkyne, maleimide or cyclopentadiene, or a group derived therefrom.

A method for inspecting hepatitis and AIDS nucleic acid by synchronized amplification and its reagent knit are disclosed. The process is carried out by taking magnetic ball as automatic medium, specific synchronized capturing HBV, CHV and HIV nucleic acid, accelerating biotin primer construction and purification by RNA external label and internal label, real-time synchronized inspecting and T-PCR amplifying based on Tagman probe. The reagent knit consists of dis-inhibitor, cracking liquid, magnetic ball suspension, washing liquor, internal check, RT-PCR reactive liquor, enzyme mixture, fluorescent mixture, positive check and negative check. It's accurate and automatic, has single-tube operation, closed inspection AND synchronized extraction, and it has better sensitivity and specific performance and can be used for large-scale blood screening and large-capacity clinical inspection.

Refrigeration-shelf-stable ready-to-feed and concentrated infant formulas prepared through an ultra-pasteurization and / or pasteurization process, comprise per five fluid ounces from about 1.8 to about 6.3 grams of protein; from about 3.3 to about 15.9 grams of fat; from about 300 mg to about 3000 mg of linoleic acid; from about 250 to about 900 IU of Vitamin A; from about 40 to about 180 IU of Vitamin D; from about 0.7 to about 9 IU of Vitamin E; from about 4 to about 24 mcg of Vitamin K; from about 40 to about 300 mcg of Thiamine (Vitamin B1); from about 60 to about 450 mcg of Riboflavin (Vitamin B2); from about 35 to about 180 mcg of Vitamin B6; from about 0.15 to about 0.9 mcg of Vitamin B12; from about 250 to about 3150 mcg of Niacin; from about 4 to about 48 mcg of Folic Acid (Folacin); from about 300 to about 1500 mcg of Pantothenic Acid; from about 1.5 to about 13.2 mcg of Biotin; from about 8 to about 36 mg of Vitamin C (Ascorbic Acid); from about 7 to about 48 mg of Choline; from about 4 to about 18 mg of Inositol; from about 60 to about 234 mg of Calcium; from about 30 to about 159 mg of Phosphorus; from about 6 to about 24 mg of Magnesium; from about 0.15 to about 5.4 mg of Iron; from about 0.5 to about 3 mg of Zinc; from about 5 to about 45 mcg of Manganese; from about 60 to about 270 mcg of Copper; from about 5 to about 75 mcg of Iodine; from about 20 to about 81 mg of Sodium; from about 80 to about 324 mg of Potassium; and from about 55 to about 195 mg of Chloride; wherein the total caloric content is from about 80 kilocalories to about 300 kilocalories per five fluid ounces.

The present invention relates to the delivery of drug, peptide and protein pharmaceuticals using a biotin-mediated uptake system. More particularly the invention relates to the amplification of active substance delivery with the biotin uptake system using a biotin-active substance-polymer conjugate or a biotin-nanoparticle conjugate. The invention also relates to processes for preparing the conjugates, pharmaceutical and diagnostic compositions containing same and methods of diagnosis and treatment involving the conjugates.

The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below.The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.

A 3-branched asparagine-linked oligosaccharide derivative of the formula (1) wherein the nitrogen of amino group of asparagine is modified with a lipophilic protective group, biotin group or FITC group; a 3-branched asparagine-linked oligosaccharide derivative which contains at least one fucose in N-acetylglucosamine on the nonreducing terminal side of the asparagine-linked oligosaccharide of the derivative; asparagine-linked oligosaccharides and oligosaccharides thereof wherein Q is a lipophilic protective group, biotin group or FITC group.

A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q10, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.

The invention relates to an immunoassay reagent kit, and discloses a dry method photic stimulation chemiluminescence immunoassay reagent kit and preparation and application thereof. The dry method photic stimulation chemiluminescence immunoassay reagent kit of the invention comprises a reaction vessel of an antigen or an antibody fixed with dry detection particles and dry biotin marks, wherein, the detection particles are luminous particles of the envelope antigen or the antibody. The kit of the invention can be used for quantitative or qualitative detection of the antigen or the antibody to be detected.

An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and / or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

The invention discloses a preparation method and the production process of a complex injection of 13 vitamins. The injection adopts dual-injection type, the invention overcomes the problem of solubility of the fat-soluble vitamins in water, so the invention can be prepared into the water injection; the stability of the product is good, and various vitamins can not be affected mutually. The injection includes water-soluble vitamins, fat-soluble vitamins, surfactant, antioxidant, complexing agent and solvent, the injection water is added till the dissolution, the activated carbon is added for absorption, the pH value of the solution is regulated, and then the nitrogen filling and sterilization are carried out. The production process of the invention prepares the injection into dual-injection type, the vitamin B12, folic acid and biotin have an independent package, the process overcomes the problem of solubility of fat-soluble vitamins in water, the invention can be prepared into water injection, the stability of the product is good, and various vitamins can not be affected mutually, the vitamins can be added in a large infusion for usage, so as to avoid the trouble of redissolution and reuse of the freeze-dried powder injection.

The invention discloses a detection kit used for detecting the serum autoantibody of mammals. The detection kit comprises an antigen protein, wherein the antigen protein is a combination of five or more out of p53, Annexin1, CAGE, NY-ESO-1, HuD, Cyclin D, PGP9.5, GBU4-5, MDM2, GAGE7, XAGE1b, SOX2, MAGE A1 and MAGE A4. The detection kit adopts a group of novel antigen combination corresponding to the autoantibody of a biomarker related to cancers, utilizes biotins to form characteristics of a polymer to envelope the antigen protein, and uses an anti-human label peptide as a standard of quantitative detection, thus increasing the detection sensibility and accuracy of the serum autoantibody, and providing an optimized detection method for using the autoantibody to carry out cancer diagnosis.

In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc post-translational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

The invention provides a feed additive for improving the quality of the fur of a furry animal. The additive is obtained by mixing a semi-finished vitamin product, a semi-finished trace element product, dihydropyridine, methionine, cystine and corn gluten meal according to a weight ratio of 1:1:0.3-1:0.2-0.9:0.1-0.6:2, wherein the semi-finished vitamin product is prepared by uniformly mixing the following components: 5-22 parts of vitamin A, 3-8 parts of vitamin D, 10-25 parts of vitamin E, 3-8 parts of vitamin B1, 8-15 parts of biotin, 1-3 parts of vitamin B6, and 120-160 parts of the corn gluten meal, and the semi-finished trace element product is prepared by uniformly mixing the following components: 10-20 parts of methionine chelated zinc, 2-5 parts of methionine chelated copper, and 70-90 parts of zeolite powder. The additive of the invention allows the quality of the fur of the furry animals (martens, foxes and raccoon dogs) to be substantially improved, the hair density to be increased, the hair length to be improved, the hide toughness to be increased and the culture benefit to be improved.

The invention provides health-care food for beautifying and brightening hair of a dog, belonging to the field of animal health-care products. The health-care food formula comprises the following components by weight based on 1kg: 10-30g of deep sea fish oil, 10-30g of linseed oil, 5-20g of poppyseed oil, 10-30g of perilla oil, 10-30g of grape seed oil, 10-30g of lecithin, 5-20g of chelate iron, 1-10g of chelate manganese, 5-20g of chelate zinc, 1-5g of chelate copper, 0.05-0.2g of yeast selenium, 150-250g of methionine, 50-150g of lysine, 1-4g of vitamin E, 0.05-0.2g of vitamin D, 0.5-2g of vitamin A, 0.05-0.2g of vitamin B1, 0.1-0.4g of vitamin B2, 0.05-0.2g of vitamin B6, 0.05-0.4g of vitamin B12, 0.05-0.2g of biotin, 0.1-0.4g of nicotinic acid, 1-5g of bacillus, 1-5g of yeast, 120-180gof chicken liver powder, 50-80g of Rosmarinus officinalis and the balance of yeast powder. The components are made into a tablet with the specification of 0.7-0.9g according to a regular tabletting process, and the water content is less than 10%. The health-care food provided by the invention has the advantages of high titer and strong stability and is capable of improving the fur health of the dog, protecting hair follicles and hair shafts against damage, enabling the hair to be smooth and soft, reducing hair slip, promoting regeneration of furs, improving immunity comprehensively and ensuring the dog in a healthy and vital state.